Skip to main content
. Author manuscript; available in PMC: 2013 Nov 15.
Published in final edited form as: Cancer. 2012 Apr 19;118(22):5663–5670. doi: 10.1002/cncr.27563

Figure 2.

Figure 2

Determination of optimal age-based starting dosages of topotecan. The final nonlinear mixed-effects model was used to perform Monte Carlo simulations of topotecan lactone plasma concentration in patients of different ages over a range of dosages. The topotecan lactone AUC calculated for each patient in the simulation was used to determine the probability of achieving the targeted 120–160 ng/mL*hr systemic exposure within each age group.